Because (P)RR-PshRNA was shown to have potential as a possible candidate drug for the treatment of AMD (Figures 1, 2, and 3), we further compared the efficiency of (P)RR-PshRNA with that of aflibercept, one of the first-line anti-VEGF drugs in clinical practice,41 for CNV and subretinal fibrosis formation. The gene discussed is VEGFA; the disease is age-related macular degeneration.